This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Food and Drug Administration, HHS.
Final rule; technical amendments.
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during September and October 2015. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect changes of sponsorship of applications and the voluntary withdrawals of approval of applications that occurred in September and October 2015.
This rule is effective December 9, 2015, except for the amendments to 21 CFR 520.446, 520.2043, 558.625, and 558.630, which are effective December 21, 2015.
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5689, george.haibel@fda.hhs.gov.
( printed page 76385)
FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during September and October 2015, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the Center for Veterinary Medicine FOIA Electronic Reading Room: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm. Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/default.htm.
| File No. | Sponsor | Product name | Action | 21 CFR section | FOIA summary | NEPA review |
|---|---|---|---|---|---|---|
| 141-440 | Piedmont Animal Health, 204 Muirs Chapel Rd., suite 200, Greensboro, NC 27410 | CLARO (florfenicol, terbinafine, mometasone furoate) Otic Solution | Original approval for the treatment of otitis externa in dogs | 524.957 | yes | CE.1 2 |
| 141-449 | Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940 | SAFE-GUARD AquaSol (fenbendazole oral suspension) Suspension Concentrate | Original approval for the treatment and control of certain nematode worms in broiler chickens, replacement chickens intended to become breeding chickens, and breeding chickens | 520.905a | yes | EA/ FONSI.3 |
| 141-442 | Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 | LUTALYSE HighCon (dinoprost tromethamine injection) Injection | Supplemental approval of subcutaneous route of administration | 522.690 | yes | CE.1 4 |
| 108-901 | Zoetis Inc. 333 Portage St., Kalamazoo, MI 49007 | LUTALYSE (dinoprost tromethamine injection) Injection | Supplemental approval of revised indications for uses in cattle | 522.690 | no | CE.1 4 |
| 1 The Agency has determined that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not have a significant effect on the human environment. | ||||||
| 2 CE granted under 21 CFR 25.33(d)(1). | ||||||
| 3 The Agency has carefully considered an environmental assessment (EA) of the potential environmental impact of this action and has made a finding of no significant impact (FONSI). | ||||||
| 4 CE granted under 21 CFR 25.33(a)(1). | ||||||
During September and October 2015, ownership of, and all rights and interest in, the following approved applications have been transferred as follows:
| File No. | Previous sponsor | Product name | New sponsor | 21 CFR section |
|---|---|---|---|---|
| 141-440 | Piedmont Animal Health, 204 Muirs Chapel Rd., suite 200, Greensboro, NC 27410 | CLARO (florfenicol, terbinafine, mometasone furoate) Otic Solution | Bayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201 | 524.957 |
| 200-582 | Orkeo USA, Inc., 77 Water St., New York, NY 10005 | LONCOR 300 (florfenicol) Injectable Solution | Bayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201 | 522.955 |
As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these changes of sponsorship. Following the change of sponsorship of ANADA 200-582, Orkeo USA, Inc., is no longer the sponsor of an approved application.
In addition, during September and October 2015, the following three sponsors have requested that FDA withdraw approval of the NADAs and ANADAs listed in the following table because the products are no longer manufactured or marketed:
| File No. | Sponsor | Product name | 21 CFR section |
|---|---|---|---|
| 140-680 1 | Pharmgate LLC, 1015 Ashes Dr., suite 102, Wilmington, NC 28405 | TYLAN (tylosin phosphate) Premix | 558.625 |
| ( printed page 76386) | |||
| 140-681 1 | Pharmgate LLC, 1015 Ashes Dr., suite 102, Wilmington, NC 28405 | TYLAN SULFA G (tylosin phosphate and sulfamethazine) Premix | 558.630 |
| 200-028 | Pegasus Laboratories, Inc., 8809 Ely Rd., Pensacola, FL 32514 | EVICT 300 (pyrantel pamoate) Suspension | 520.2043 |
| 200-383 | Bayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201 | CLINDAROBE (clindamycin) Capsules | 520.446 |
| 1 These NADAs were identified as being affected by guidance for industry #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209,” December 2013. | |||
Elsewhere in this issue of the Federal Register , FDA gave notice that approval of NADA 140-680, NADA 140-681, ANADA 200-028, and ANADA 200-383, and all supplements and amendments thereto, is withdrawn, effective December 21, 2015. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these voluntary withdrawals of approval.
FDA has noticed that a previous sponsor of ANADA 200-383, Teva Canada Ltd., was no longer the sponsor of an approved application following a prior change of sponsorship. At this time, FDA is amending the regulation to remove the firm from the listings of sponsors of approved applications in 21 CFR 510.600. This action is being taken to improve the accuracy of the regulations.
FDA is also revising the special considerations for medicated feeds containing veterinary feed directive drugs to align with 21 CFR 558.6(a)(6), which was recently amended (80 FR 31708, June 3, 2015). This action is being taken to improve the consistency of the regulations.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability”. Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, and 558 are amended as follows:
1. The authority citation for 21 CFR part 510 continues to read as follows:
2. In § 510.600:
a. In the table in paragraph (c)(1), remove the entries for “Orkeo USA, Inc.” and “Teva Canada Ltd.”; and
b. In the table in paragraph (c)(2), remove the entries for “043806” and “086050”.
3. The authority citation for 21 CFR part 520 continues to read as follows:
4. Effective December 21, 2015, in § 520.446, in paragraph (b)(1), remove “Nos. 000859 and 054771” and in its place add “No. 054771”.
5. In § 520.905a:
a. Revise paragraphs (a) and (e)(4)(i);
b. In paragraph (e)(4)(iii), remove the first sentence; and
c. Add paragraph (e)(5).
The revisions and addition read as follows:
(a) Specifications. Each milliliter of suspension contains 100 milligrams (mg) fenbendazole for use as in paragraphs (e)(1), (2), (3), and (4) of this section; or 200 mg fenbendazole for use as in paragraph (e)(5) of this section.
(e) * * *
(4) * * *
(i) Amount. Administer orally 5 mg/kg of body weight (2.3 mg/lb). Retreatment may be needed after 4 to 6 weeks.
(5) Chickens —(i) Amount. Administer orally via drinking water at a daily dose of 1 mg/kg body weight (0.454 mg/lb) for 5 consecutive days.
(ii) Indications for use. For the treatment and control of adult Ascaridia galli in broiler chickens and replacement chickens intended to become breeding chickens, and for the treatment and control of adult A. galli and Heterakis gallinarum in breeding chickens.
(iii) Limitations. Not for use in laying hens and replacement chickens intended to become laying hens.
6. Effective December 21, 2015, in § 520.2043, in paragraph (b)(2), remove “Nos. 054771, 055246, 058829, and 059130” and in its place add “Nos. 000859, 054771, and 058829”.
7. The authority citation for 21 CFR part 522 continues to read as follows:
8. In § 522.690, revise paragraphs (b)(2) and (d)(1)(i) and add paragraph (b)(3) to read as follows:
(b) * * *
(2) No. 054771 for use of the 5 mg/mL product as in paragraphs (d)(1), (2), and (3) of this section.
(3) No. 000859 for use of the 5 mg/mL product as in paragraphs (d)(2), (3), and (4) of this section.
(d) * * *
(1) * * *
(i) Amount. 25 mg as a single intramuscular or subcutaneous injection.
9. In § 522.955(b)(2), remove “086050” and in its place add “000859”.
10. The authority citation for 21 CFR part 524 continues to read as follows:
11. Add § 524.957 to read as follows:
(a) Specifications. Each single-dose, prefilled dropperette contains 1 milliliter (mL) of a solution containing 15 milligrams (mg) florfenicol, 13.3 mg terbinafine, and 2 mg mometasone furoate.
(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs —(1) Amount. Administer one dropperette (1 mL) per affected ear(s).
(2) Indications for use. For the treatment of otitis externa in dogs associated with susceptible strains of yeast ( Malassezia pachydermatis) and bacteria ( Staphylococcus pseudintermedius).
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
12. The authority citation for 21 CFR part 558 continues to read as follows:
13. In § 558.68, revise paragraph (c)(1) to read as follows:
(c) * * *
(1) Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See § 558.6 for additional requirements.
14. In § 558.261, revise paragraphs (c)(1) and (2) introductory text to read as follows:
(c) * * *
(1) Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See § 558.6 for additional requirements.
(2) The expiration date of VFDs for florfenicol medicated feeds:
15. In § 558.618, revise paragraph (c)(1) to read as follows:
(c) * * *
(1) Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See § 558.6 for additional requirements.
16. Effective December 21, 2015, in § 558.625, remove paragraph (b)(5) and redesignate paragraph (b)(6) as paragraph (b)(5).
17. Effective December 21, 2015, in § 558.630, in paragraph (b)(2), remove “Nos. 054771 and 069254” and in its place add “No. 054771”.
Dated: December 4, 2015.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2015-31042 Filed 12-8-15; 8:45 am]
BILLING CODE 4164-01-P